Literature DB >> 11943265

HMG CoA reductase inhibitor (statin) and aortic valve calcium.

David M Shavelle1, Junichuro Takasu, Matthew J Budoff, SongShou Mao, Xue Qiao Zhao, Kevin D O'Brien.   

Abstract

There is no known pharmacological therapy for calcific aortic valvular sclerosis or stenosis. Because leaflet calcification occurs in areas of lipoprotein deposition, we hypothesised that 3-hydroxy-3-methylglutaryl-coenzyme A (HMG COA) reductase inhibitors (statins) might slow aortic valve calcium (AVC) accumulation. We retrospectively identified 65 patients who had undergone two electron-beam computed tomography scans at a mean (SD) interval of 2.5 (1.6) years. 28 (43%) patients were receiving statins. Patients who were treated with statins had a 62-63% lower median rate of AVC accumulation (p=0.006) and 44-49% fewer statin patients had definite AVC progression (p=0.043). These findings suggest that statins may decrease AVC accumulation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943265     DOI: 10.1016/S0140-6736(02)08161-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

Review 1.  Calcific aortic stenosis: from bench to the bedside--emerging clinical and cellular concepts.

Authors:  Nalini M Rajamannan; Bernard Gersh; Robert O Bonow
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

2.  Targeted therapy to prevent progression of calcific aortic stenosis.

Authors:  Nalini M Rajamannan; Catherine M Otto
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

Review 3.  The role of phosphorus in the development and progression of vascular calcification.

Authors:  Jessica Kendrick; Michel Chonchol
Journal:  Am J Kidney Dis       Date:  2011-09-28       Impact factor: 8.860

Review 4.  Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.

Authors:  Nalini M Rajamannan; Frank J Evans; Elena Aikawa; K Jane Grande-Allen; Linda L Demer; Donald D Heistad; Craig A Simmons; Kristyn S Masters; Patrick Mathieu; Kevin D O'Brien; Frederick J Schoen; Dwight A Towler; Ajit P Yoganathan; Catherine M Otto
Journal:  Circulation       Date:  2011-10-18       Impact factor: 29.690

5.  Is it time for medical therapy for aortic valve disease?

Authors:  Nalini M Rajamannan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

Review 6.  Asymptomatic valvular disease: who benefits from surgery?

Authors:  Naomi F Botkin; Paula S Seth; Gerard P Aurigemma
Journal:  Curr Cardiol Rep       Date:  2005-03       Impact factor: 2.931

7.  Anti-inflammatory effect of amlodipine plus atorvastatin treatment on carotid atherosclerosis in zucker metabolic syndrome rats.

Authors:  Xuemei Zhang; Fengfeng Tian; Hiromi Kawai; Tomoko Kurata; Shoko Deguchi; Kentaro Deguchi; Jingwei Shang; Ning Liu; Wentao Liu; Yoshio Ikeda; Tohru Matsuura; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2012-07-21       Impact factor: 6.829

8.  Three dimensional volume quantification of aortic valve calcification using multislice computed tomography.

Authors:  G J Morgan-Hughes; P E Owens; C A Roobottom; A J Marshall
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

9.  Association of aortic valve calcification to the presence, extent, and composition of coronary artery plaque burden: from the Rule Out Myocardial Infarction using Computer Assisted Tomography (ROMICAT) trial.

Authors:  Amir A Mahabadi; Fabian Bamberg; Michael Toepker; Christopher L Schlett; Ian S Rogers; John T Nagurney; Thomas J Brady; Udo Hoffmann; Quynh A Truong
Journal:  Am Heart J       Date:  2009-10       Impact factor: 4.749

Review 10.  Using noncontrast cardiac CT and coronary artery calcification measurements for cardiovascular risk assessment and management in asymptomatic adults.

Authors:  John A Rumberger
Journal:  Vasc Health Risk Manag       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.